Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CHRS
STRONG SELLCoherus Oncology, Inc. · Healthcare · United States · $217M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing biosimilar and innovative oncology products. The company's competitive advantage lies in its expertise in navigating complex regulatory pathways for biosimilars, offering cost-effective alternatives to established biologics and strategically expanding its portfolio to address unmet needs in cancer treatment.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 211.0M | 257.2M | 26.4M | 42.2M | -41.5% | 46.9M | 73.0M | 100.1M | 54.0% |
| EPS | -3.81 | -3.76 | -2.53 | 0.25 | 1.43 | 472.0% | -1.43 | 2.08 | 1.31 | -4.3% |
| Shares | — | 78.9M | 112.2M | 115.6M | 121.2M | +53.6% | 154.2M | — | — | — |
| Debt | — | 480.4M | 480.8M | 269.9M | 40.3M | -56.2% | 54.4M | — | — | — |
| Equity | — | -137.4M | -193.4M | -132.0M | 61.0M | — | — | — | — | — |
| Op CF | — | -241.1M | -174.9M | -20.4M | -138.5M | — | -170.6M | — | — | — |
| Inv CF | — | -166.8M | 144.6M | 230.3M | 375.1M | — | — | — | — | — |
| Fin CF | — | 54.3M | 69.6M | -187.0M | -273.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CHRS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CHRS | Coherus Oncology, Inc.(you) | $217M | 17 | STRONG SELL |
| KROS | Keros Therapeutics, Inc. | $199M | 18 | STRONG SELL |
| SRZN | Surrozen, Inc. | $229M | 15 | STRONG SELL |
| NAUT | Nautilus Biotechnology, Inc. | $215M | 15 | STRONG SELL |
| RNA | Atrium Therapeutics, Inc. | $197M | 16 | STRONG SELL |
| NERV | Minerva Neurosciences, Inc. | $188M | 16 | STRONG SELL |
| VYGR | Voyager Therapeutics, Inc. | $187M | 15 | STRONG SELL |
| FULC | Fulcrum Therapeutics, Inc. | $248M | 14 | STRONG SELL |
| OBIO | Orchestra BioMed Holdings, Inc. | $224M | 22 | SELL |
| IRD | Opus Genetics, Inc. | $254M | 14 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%